<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7000641\results\search\drugs\results.xml">
  <result pre="spondylitis revealed good antibody responses, regardless of the time of" exact="infliximab" post="infusion [68]. In patients prescribed both an immunomodulator and"/>
  <result pre="monotherapy with an immunomodulator, anti-TNF, or 5-ASAs [69]. In contrast," exact="vedolizumab" post="which shows gut-selective mechanism does not influence the response"/>
  <result pre="IBD who are receiving anti-TNF, such as infliximab, etanercept, or" exact="adalimumab" post="[86,92-96]. In two large, retrospective cohort studies, liver dysfunction"/>
  <result pre="listed in Table 3. Long-term moderate-to-high dose corticosteroid therapy (oral" exact="prednisone" post="≥ 10 mg/day over 4 weeks) increases the risk"/>
  <result pre="HBsAg-negative plus anti-HBc positive [98]. Long-term, low-dose corticosteroid therapy (oral" exact="prednisone" post="of less than 10 mg/day over 4 weeks) may"/>
  <result pre="which necessitates antiviral prophylaxis. In contrast, patients receiving shortterm oral" exact="prednisone" post="over 1 week are at low risk of reactivation"/>
  <result pre="do not need antiviral prophylaxis [98]. Immunophilin inhibitors such as" exact="cyclosporine" post="and tacrolimus may increase the likelihood of HBV reactivation"/>
  <result pre="need antiviral prophylaxis [98]. Immunophilin inhibitors such as cyclosporine and" exact="tacrolimus" post="may increase the likelihood of HBV reactivation [100]. However,"/>
  <result pre="the likelihood of HBV reactivation [100]. However, patients receiving methotrexate," exact="azathioprine" post="or 6-mercaptopurine do not require antiviral prophylaxis because they"/>
  <result pre="low risk of HBV reactivation [98]. Anti-TNF treatments, such as" exact="infliximab" post="and adalimumab, confer a high risk of HBV reactivation—up"/>
  <result pre="are HBsAg-positive [95,101]. Furthermore, this risk is higher when using" exact="infliximab" post="than when using etanercept, which is correlated with potency."/>
  <result pre="immunosuppressive therapy—most literature specifies 7 days before [107]. Entecavir and" exact="tenofovir" post="are preferred to other antiviral agents, because they have"/>
  <result pre="reactivation beyond 12 months reported, particularly in patients who received" exact="rituximab" post="(antiCD20 antibody) [110-112]. 5. Monitoring Statement 8 HBV status"/>
  <result pre="patients with IBDNat Rev Gastroenterol Hepatol20131027728523419290 68ElkayamOBashkinAMandelboimMet al.The effect of" exact="infliximab" post="and timing of vaccination on the humoral response to"/>
  <result pre="and future directionsGastroenterology20171521297130928219691 84LoombaRRowleyAWesleyRet al.Systematic review: the effect of preventive" exact="lamivudine" post="on hepatitis B reactivation during chemotherapyAnn Intern Med200814851952818378948 85YeoWChanPKZhongSet"/>
  <result pre="after immunosuppressive or cytotoxic chemotherapyJ Gastroenterol2016511081108926943169 92XuZDaiWWuYTet al.Prophylactic effect of" exact="lamivudine" post="on chemotherapy-induced hepatitis B virus reactivation in patients with"/>
  <result pre="anti-tumor necrosis factor-alpha therapyJ Rheumatol2009362416242019797507 95EsteveMSaroCGonzález-HuixFSuarezFFornéMViverJMChronic hepatitis B reactivation following" exact="infliximab" post="therapy in Crohn’s disease patients: need for primary prophylaxisGut2004531363136515306601"/>
  <result pre="B virus cccDNAScience20143431221122824557838 103KoskinasJTampakiMDoumbaPPRallisEHepatitis B virus reactivation during therapy with" exact="ustekinumab" post="for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patientBr"/>
  <result pre="in liver diseaseGastroenterology201414757759425066692 106MozessohnLChanKKFeldJJHicksLKHepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving" exact="rituximab" post="for lymphoma: a meta-analysisJ Viral Hepat20152284284925765930 107ZhangMYZhuGQShiKQet al.Systematic review"/>
  <result pre="prevention of chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic" exact="entecavir" post="or lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet"/>
  <result pre="chemotherapy-induced hepatitis B virus reactivationOncotarget20167306423065827121321 108YangCQinBYuanZChenLZhouHYMeta-analysis of prophylactic entecavir or" exact="lamivudine" post="against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of"/>
  <result pre="lamivudine against hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of" exact="entecavir" post="and lamivudine in preventing HBV reactivation in lymphoma patients"/>
  <result pre="hepatitis B virus reactivationAnn Hepatol20161550151127236149 109YuSLuoHPanMet al.Comparison of entecavir and" exact="lamivudine" post="in preventing HBV reactivation in lymphoma patients undergoing chemotherapy:"/>
  <result pre="Clin Pharm2016381035104327450506 110CervaCColagrossiLMaffongelliGet al.Persistent risk of HBV reactivation despite extensive" exact="lamivudine" post="prophylaxis in haematopoietic stem cell transplant recipients who are"/>
  <result pre="cyclosporine)  Low risk (&amp;lt;1%) Short-term corticosteroids (≤1 week) Noa Azathioprine/6-mercaptopurine," exact="methotrexate" post="HBsAg-negative/anti-HBc-positive  High risk (≥ 10%) Not available Yes  Moderate"/>
  <result pre="low-dose corticosteroids (prednisone &amp;lt; 10 mg/day, ≥ 4 weeks) Azathioprine/6-mercaptopurine," exact="methotrexate" post="aPreemptive therapy."/>
 </snippets>
</snippetsTree>
